| Dry Eye Syndromes
Miebo vs Xiidra
Side-by-side clinical, coverage, and cost comparison for dry eye syndromes.Deep comparison between: Miebo vs Xiidra with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsXiidra has a higher rate of injection site reactions vs Miebo based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Xiidra but not Miebo, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Miebo
Xiidra
At A Glance
Topical (ophthalmic)
4 times daily
Semifluorinated alkane
Ophthalmic
Twice daily
LFA-1 antagonist
Indications
- Dry Eye Syndromes
- Dry Eye Syndromes
Dosing
Dry Eye Syndromes Instill one drop four times daily into each affected eye; remove contact lenses prior to and for at least 30 minutes after administration.
Dry Eye Syndromes Instill one drop twice daily (approximately 12 hours apart) into each eye using a single-use container; remove contact lenses prior to administration and reinsert 15 minutes after.
Contraindications
- History of hypersensitivity reaction to perfluorohexyloctane
- Known hypersensitivity to lifitegrast or any other ingredient in the formulation
Adverse Reactions
Most common (<4%) blurred vision, conjunctival redness
Premarketing studies hypersensitivity
Most common (>=5%) Instillation-site irritation, dysgeusia, reduced visual acuity
Common (1%-5%) Blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus, sinusitis
Postmarketing Hypersensitivity reactions including anaphylactic reaction, bronchospasm, respiratory distress, pharyngeal edema, swollen tongue, urticaria, allergic conjunctivitis, dyspnea, angioedema, allergic dermatitis, eye swelling, rash
Pharmacology
Perfluorohexyloctane, a semifluorinated alkane, forms a monolayer at the air-liquid interface of the tear film that may reduce evaporation; the exact mechanism of action in dry eye disease is not known.
LFA-1 antagonist; lifitegrast binds to integrin LFA-1 on leukocytes, blocking its interaction with ICAM-1 and inhibiting T-cell adhesion and migration, thereby reducing inflammation in dry eye disease.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Miebo
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (11/12)
Xiidra
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Miebo
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (6/8)
Xiidra
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (6/8)
Humana
Miebo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Xiidra
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Thyroid Eye Disease (TED)
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Xiidra.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.